The multinational, prospective, randomized, double-blind study will evaluate the effectiveness of AMR101 in reducing the prevalence of first major cardiovascular events in a high-risk patient population.
Amarin chairman and CEO Joseph Zakrzewski said that the results of REDUCE-IT may enable them to seek additional indications for AMR101 including cardiovascular prevention.